To hear about similar clinical trials, please enter your email below
Trial Title:
Role of Inflammatory Markers in Sepsis
NCT ID:
NCT06111963
Condition:
Diagnostic
Conditions: Official terms:
Sepsis
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
Serology tests
Description:
CD4, CD25, IL17
Arm group label:
Non Septic patients
Arm group label:
Septic patients
Summary:
A diagnostic and prognostic study, in which the expression of CD64 in activated
neutrophils and CD64 and IL17A regulatory T cells in patients with sepsis will be
evaluated as a probable marker for sepsis as a primary objective
Criteria for eligibility:
Study pop:
Postoperative patients
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Cancer patients admitted to the surgical ICU following cancer related surgeries and
diagnosed with sepsis
Exclusion Criteria:
- Refusal of patient or patient guardian to participate.
- Intraoperative massive blood loss and massive blood transfusion
- Patients with impaired preoperative kidney or liver function tests
Gender:
All
Minimum age:
18 Years
Maximum age:
65 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Walaa Y Elsabeeny
Address:
City:
Cairo
Zip:
11796
Country:
Egypt
Status:
Recruiting
Contact:
Last name:
Walaa Y Elsabeeny, MD
Phone:
+201007798466
Email:
walaa.elsabeeny@nci.cu.edu.eg
Contact backup:
Last name:
Ahmed Samir, MD
Phone:
+201097781290
Email:
ahmed.samir@nci.cu.edu.eg
Start date:
November 1, 2023
Completion date:
August 2024
Lead sponsor:
Agency:
National Cancer Institute, Egypt
Agency class:
Other
Source:
National Cancer Institute, Egypt
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06111963
